Skip to main content

Table 2 Post-Event Pharmacologic Treatment of Participants With and Without Heart Failure

From: Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone

  Hospitalized Heart Failure* Treated, Nonhospitalized Heart Failure* Without Heart Failure
  C D C D C D
No. of participants 232 281 93 145 14493 8347
Post-event medication       
   Blinded medication, (%) 83 (35.8) 126 (44.8) 54 (58.1) 93 (64.1) 11247 (77.6) 6096 (73.0)
   Open-label diuretic (%) 135 (58.2) 180 (64.0) 57 (61.3) 98 (67.6) 1279 (8.8) 1153 (13.8)
   Open-label ACE-inhibitor (%) 90 (38.8) 114 (40.5) 31 (33.3) 44 (30.3) 1154 (8.0) 826 (9.9)
   Open-label beta-blocker (%) 33 (14.2) 38 (13.5) 18 (19.4) 32 (22.1) 3149 (21.7) 2016 (24.0)
   Open-label diuretic, ACE-inhibitor or beta-blocker (%) 169 (72.8) 210 (74.8) 72 (77.4) 119 (82.1) 4829 (33.3) 3347 (40.1)
  1. C = Chlorthalidone treatment group D = Doxazosin treatment group ACE = Angiotensin converting enzyme *Represents data as of first clinic visit after event. Represents data as of most recent clinic visit. All participants represented have at least one follow-up visit. 355 chlorthalidone and 229 doxazosin participants are excluded due to lack of at least one follow-up visit.